Hypha Discovery Signs Natural Products Drug Discovery Collaboration with Ferrer Grupo
|| Print ||
|Tuesday, 27 September 2011 16:15 (UTC + 2)|
London, UK, September 27, 2011 / B3C newswire / – Hypha Discovery Ltd (Hypha) today announced a collaboration with Ferrer Grupo to mine Hypha's MycoDiverse™ library to discover novel low molecular weight natural products to treat microbial infections.
Hypha's library will provide an important complement to Ferrer's synthetic chemistry-driven discovery programme.
The MycoDiverse™ library is a collection of 10,000 refined fractions from fermentations of higher fungi, generated using Hypha’s proprietary technology to stimulate secondary metabolite production. This powerful technology unlocks the potential of this under-exploited group of microbes to produce bioactive chemistry with very high structural novelty. The collection contains a very high percentage of relatively low molecular weight (MW <500) and undescribed compounds and is a proven source of novel lead compounds against “difficult” therapeutic targets, including protein-protein interactions.
Hypha’s CEO, Dr Liam Evans said “We recognise the challenges facing the discovery of novel antibiotics and firmly believe that pairing our technology with Ferrer’s experience and excellence in pharmaceutical R&D represents an ideal fit and we are pleased to be working in collaboration with scientists who recognise the potential of our technology and discovery resources.”
Ferrer’s R&D Director, Dr Antonio Guglietta, said “we are very excited about the collaboration with Hypha since we see a high degree of complementarity between Hypha’s’ expertise and skill in the field of natural products and ours in the discovery and development of new anti-microbial drugs. We expect this complementarity to be especially fruitful in the discovery of new niche antimicrobial cures, a therapeutic area to which Ferrer is highly committed”.
About Hypha Discovery Ltd
About Ferrer Grupo